Susquehanna Fundamental Investments, LLC Nurix Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $404,041 - $649,153	-32,769 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $34,782 - $79,699	2,688 Added 8.94%	32,769 $459,000
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $35,971 - $46,954	-1,361 Reduced 4.33%	30,081 $871,000
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $714,047 - $1.15 Million	31,442 New	31,442 $942,000
Q1 2021 May 17, 2021	SELL	$26.98 - $50.17 $223,934 - $416,411	-8,300 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$22.85 - $48.44 $15,995 - $33,908	-700 Reduced 7.78%	8,300 $273,000
Q3 2020 Nov 16, 2020	BUY	$16.05 - $34.91 $144,450 - $314,189	9,000 New	9,000 $314,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.